(Total Views: 628)
Posted On: 10/15/2019 3:18:43 PM
Post# of 72448
I just reread yesterday's PR and found the following paragraph very interesting:
"Significant premiums are being paid for novel oral IBD treatments in development—whether via lucrative licensing agreements (e.g., Janssen and Theravance Biopharma, Janssen and Protagonist Therapeutics), or via direct investments from venture capital (e.g., Xontogeny and Landos Biopharma"
I have always assumed IPIX would continue a strategy of royalty based license deals but found it interesting that the door may be open for a VC deal. The Locust arrangement may provide some interesting options.
"Significant premiums are being paid for novel oral IBD treatments in development—whether via lucrative licensing agreements (e.g., Janssen and Theravance Biopharma, Janssen and Protagonist Therapeutics), or via direct investments from venture capital (e.g., Xontogeny and Landos Biopharma"
I have always assumed IPIX would continue a strategy of royalty based license deals but found it interesting that the door may be open for a VC deal. The Locust arrangement may provide some interesting options.
(10)
(1)
